A Comprehensive Review on Neturaceuticals in Alzheimer’s and Neurodegenerative Disease an Cognitive Enhancement

Year : 2025 | Volume : 02 | Issue : 01 | Page : 1 9
    By

    Mohd. Wasiullah,

  • Piyush Yadav,

  • Anita Yadav,

  • Dileep Kumar Yadav,

  1. Principal, Dept. of Pharmacy, Prasad Institute of Technology, Jaunpur (222001) U.P, India
  2. Academic Head, Dept. of Pharmacy, Prasad Institute of Technology, Jaunpur (222001) U.P, India
  3. Lecturer, Dept. of Pharmacy, Prasad Institute of Technology, Jaunpur (222001) U.P, India
  4. Scholar, Dept. of Pharmacy, Prasad Institute of Technology, Jaunpur (222001) U.P, India

Abstract

Neurodegenerative diseases, including Alzheimers disease (AD), Parkinsons disease (PD), and related cognitive disorders, represent a significant and growing public health challenge, particularly in aging populations. Despite advances in pharmacological treatments, therapeutic options for cognitive decline and neurodegeneration remain limited. Recent interest has shifted towards nutraceuticals— bioactive compounds derived from food or natural sources—as promising adjuncts or alternatives in the management of these conditions. This review examines how nutraceuticals can help prevent and treat neurodegenerative illnesses, with a focus on their mechanisms of action, efficacy, and therapeutic potential. Numerous bioactive compounds found in natural foods and medicinal herbs have been shown to enhance cognitive function, including memory, attention, and learning. These substances affect cellular functions like neurogenesis, synaptogenesis, synaptic transmission, neuroinflammation, oxidative stress, and neuronal survival as well as brain metabolism. Furthermore, nutraceuticals can promote neuroplasticity, neuroprotection, and cognitive enhancement by modulating key pathways involved in brain function. The ability of nutraceuticals to influence these diverse biological processes underscores their potential as effective agents for brain health. As such, food-based strategies, including dietary supplements and functional foods enriched with nutraceuticals, represent a promising approach to improving cognitive function and potentially mitigating the impact of neurodegenerative diseases.

Keywords: Neutraceuticals, Alzheimer’s disease (AD), Neurodegenerative diseases, Phosphatidylserine, Neuroprotective, Cognitive decline

[This article belongs to International Journal of Brain Sciences ]

How to cite this article:
Mohd. Wasiullah, Piyush Yadav, Anita Yadav, Dileep Kumar Yadav. A Comprehensive Review on Neturaceuticals in Alzheimer’s and Neurodegenerative Disease an Cognitive Enhancement. International Journal of Brain Sciences. 2025; 02(01):1-9.
How to cite this URL:
Mohd. Wasiullah, Piyush Yadav, Anita Yadav, Dileep Kumar Yadav. A Comprehensive Review on Neturaceuticals in Alzheimer’s and Neurodegenerative Disease an Cognitive Enhancement. International Journal of Brain Sciences. 2025; 02(01):1-9. Available from: https://journals.stmjournals.com/ijbs/article=2025/view=203680


References

  1. Onaolapo AY, Obelawo AY, Onaolapo OJ. Brain ageing, cognition and diet: A review of the emerging roles of food-based nootropics in mitigating age-related memory decline. Curr Aging Sci. 2019;12(1):2-14.
  2. Boccardi V, Tinarelli C, Mecocci P. Nutraceuticals and cognitive dysfunction. In: Neuroprotective Effects of Phytochemicals in Neurological Disorders. Wiley; 2017. p. 561-579.
  3. Santini A, Novellino E. Nutraceuticals – shedding light on the grey area between pharmaceuticals and food. Expert Rev Clin Pharmacol. 2018;11(6):545-547.
  4. Kumar A, et al. Experimental evidence and mechanism of action of some popular neuro-nutraceutical herbs. Neurochem Int. 2021;149:105124.
  5. Hang L, Basil AH, Lim KL. Nutraceuticals in Parkinson’s disease. Neuromol Med. 2016;18(3):306-321.
  6. Vyas S, Kothari SL, Kachhwaha S. Nootropic medicinal plants: Therapeutic alternatives for Alzheimer’s disease. J Herb Med. 2019;17-18:100291.
  7. Uddin MS, et al. Nootropic and anti-Alzheimer’s actions of medicinal plants: Molecular insight into therapeutic potential to alleviate Alzheimer’s neuropathology. Mol Neurobiol. 2019;56(7):4925-4944.
  8. Giacalone M, et al. Blueberry polyphenols and neuroprotection. In: Watson RR, Preedy VR, editors. Bioactive Nutraceuticals and Dietary Supplements in Neurological and Brain Disease. Academic Press; 2015. p. 17-28.
  9. Herrup K. Reimagining Alzheimer’s disease—an age-based hypothesis. J Neurosci. 2010;30(50):16755-16762.
  10. Breijyeh Z, Karaman R. Comprehensive review on Alzheimer’s disease: Causes and treatment. Molecules. 2020;25(24):5789.
  11. Zhang XX, Tian Y, Wang ZT, Ma YH, Tan L, Yu JT, et al. The epidemiology of Alzheimer’s disease: Modifiable risk factors and prevention. J Prev Alzheimers Dis. 2021;8(3):313-321.
  12. Babcock KR, et al. Adult hippocampal neurogenesis in aging and Alzheimer’s disease. Stem Cell Reports. 2021;16(4):681-693.
  13. Rajendran L, et al. Alzheimer’s disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A. 2006;103(30):11172-11177.
  14. Munro KM, et al. Functions of the Alzheimer’s disease protease BACE1 at the synapse in the central nervous system. J Mol Neurosci. 2016;60(3):305-315.
  15. Nie Vartak A, Li YM. γ-Secretase inhibitors and modulators: Mechanistic insights into the function and regulation of γ-secretase. Semin Cell Dev Biol. 2020;105:43-53.
  16. Wischik CM, et al. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A. 1988;85(13):4884-4888.
  17. Luna-Muñoz J, et al. Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer’s disease. J Alzheimers Dis. 2007;12(4):365-375.
  18. Greenberg SM, et al. Secreted beta-amyloid precursor protein stimulates mitogen-activated protein kinase and enhances tau phosphorylation. Proc Natl Acad Sci U S A. [Year; Volume(Issue): Page numbers].
  19. Baumann K, Mandelkow EM, Biernat J, Piwnica-Worms H, Mandelkow E, et al. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett. 1993;336(3):417-424.
  20. Ghosh A, Giese K. Calcium/calmodulin-dependent kinase II and Alzheimer’s disease. Mol Brain. 2015;8(1):78.
  21. Stoothoff WH, Johnson GV. Tau phosphorylation: Physiological and pathological consequences. Biochim Biophys Acta. 2005;1739(2-3):280-297.
  22. Vecchio I, Sorrentino L, Paoletti A, Marra R, Arbitrio M, et al. The state of the art on acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease. J Cent Nerv Syst Dis. 2021;13:11795735211029113.
  23. Jimenez-Balado J, Eich TS. GABAergic dysfunction, neural network hyperactivity and memory impairments in human aging and Alzheimer’s disease. Semin Cell Dev Biol. 2021;116:146-159.
  24. Czapski GA, Strosznajder JB. Glutamate and GABA in microglia-neuron cross-talk in Alzheimer’s disease. Int J Mol Sci. 2021;22(21):11677.
  25. Mango D, et al. Targeting synaptic plasticity in experimental models of Alzheimer’s disease. Front Pharmacol. 2019;10:778.
  26. Huang YR, Liu RT. The toxicity and polymorphism of beta-amyloid oligomers. Int J Mol Sci. 2020;21(12):4477.
  27. Zheng Y, Zhu G, He J, Wang G, Li D, Zhang F, et al. Icariin targets Nrf2 signaling to inhibit microglia-mediated neuroinflammation. Int Immunopharmacol. 2019;73:304-311.
  28. Sweeney MD, Sagare A, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer’s disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14(3):133-150.
  29. Atri A. The Alzheimer’s disease clinical spectrum: Diagnosis and management. Med Clin North Am. 2019;103(2):263-293.
  30. Silveira IA, et al. Screening neuroprotective compounds in herpes-induced Alzheimer’s disease cell and 3D tissue models. Free Radic Biol Med. 2022;186.
Regular Issue Subscription Review Article
Volume 02
Issue 01
Received 14/12/2024
Accepted 03/01/2025
Published 14/01/2025
Publication Time 31 Days
368

Login


My IP

PlumX Metrics